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Summary 
We report the case of a patient who died from the rare but increasingly recognised complication of 
Listeriosis in the immediate phase following Alemtuzumab escalation therapy one month after 
discontinuing dimethyl fumarate. There is considerable overlap with typical post-infusion symptoms 
therefore high surveillance and low threshold for empirical or possible prophylactic antibiotic 
therapy is advocated.  
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Introduction 
The benefits from large-scale use of potent 
immunomodulatory therapy for relapse 
suppression in multiple sclerosis are 
accompanied by an array of very real general 
and treatment-specific risks.  
The use of the anti-CD52 humanised 
monoclonal antibody Alemtuzumab comes 
with a broad awareness and vigilance for well-
recognised and largely delayed autoimmune 
complications (1-6) and the more immediate, 
infusion-related events that can be serious in 
approximately 3% of cases (2, 4, 7). 
To date there have also been 4 reported cases 
of listeriosis which have resulted in 
syndromes of acute meningitis (8, 9) or 
listeriosis (10) with sepsis specifically during 
the broad immune-deplete phase in the days-
weeks following completion of Alemtuzumab 
infusion cycles (10-13).  Although 
approximately 9200 patients have now 
received this therapy for the indication of 
multiple sclerosis (14) suggesting this 
occurrence is relatively rare. A high index of 
suspicion and low threshold for intervention is 
required for listeriosis as its presentation may 
be clouded by common symptoms associated 
with Alemtuzumab. Furthermore, effective 
treatment is readily available but risk of 
immediate mortality is high. 
We present the first case of mortality due to 
confirmed listeriosis which arose after 
completion of the first Alemtuzumab infusion 
  
cycle and discuss some important 
considerations.  
Case Description 
A 42-year-old Caucasian lady was diagnosed 
with Relapsing Remitting multiple sclerosis in 
May 2014 after presenting with a central 
sensory syndrome.  She gave a past history of 
diplopia in 1997. In May 2014 she experienced 
a sensory relapse. In March 2015 she 
developed impaired dexterity of her left hand 
consistent with relapse. Her MRI and CSF 
oligoclonal studies were supportive of an MS 
diagnosis meeting modified McDonald criteria 
(15) and she elected to commence dimethyl 
fumarate in July 2015.  
This was well tolerated however new sensory 
disturbance arose in August 2015. Dimethyl 
fumarate was continued.  She then had a 
further relapse in April 2016 when neurogenic 
pain and new sensory disturbance arose 
necessitating use of methylprednisolone. 
Predominant but incomplete recovery 
followed and consideration of escalating 
treatment began. After counselling regarding 
options available according to NICE Guidelines 
2014 (16) the patient elected to pursue 
Alemtuzumab but wished to defer until after 
completing a family vacation.  
Dimethyl Fumarate was discontinued in July 
2016. Contemporaneous brain MRI showed 
stable appearances and her Expanded 
Disability Severity Scale score was 2.5, with 
Functional System Scores of Cerebral 2, 
Sensory 2, Sphincters 1, Cerebellar 1 and all 
else 0. Ambulation was unrestricted. The 
patient was symptomatic of noticeable short-
term memory difficulties, neuropathic pain 
and fatigue. Her only other medical 
background included hypothyroidism. 
Medications included Levothyroxine 75 
micrograms daily, Pregabalin 300mg twice 
daily, and Duloxetine 60mg daily. 
One month after Dimethyl Fumarate cessation 
Alemtuzumab 12mg was administered 
intravenously for 5 days, with concurrent 1 
gram Methylprednisolone intravenously for 
the first 3 days as per recommended delivery 
(17).     
On the second day of administration low- 
grade and non-limiting headache symptoms 
were reported. In the absence of abnormal 
observations, constitutional upset or new 
neurological symptoms, administration 
continued uneventfully with eventual 
discharge on standard symptomatic and 
prophylactic medication. 
Follow up blood count monitoring at day 5 
post-completion revealed anticipated 
decrements in haematological indices [see 
table 1], with reported persistence of the 
same low-grade headache symptoms without 
pyrexia or wider features.  
At day 6 post-completion, a 3 day history of 
diarrhoea and vomiting with general malaise 
was reported and healthcare provider review 
planned. Rapid deterioration supervened with 
the patient found in a pyrexial, unresponsive 
state at home with respiratory distress. 
Paramedic attenders found the patient 
comatose (GCS 7; E4, V2, M1) with severe 
tachypnoea (60 breaths/minute), high-grade 
pyrexia of 40oC, tachycardia 176 bpm and a 
Blood Pressure of 152/96mmHg. She was 
intubated at the scene and transferred to 
hospital. 
Volume resuscitation was commenced and 
broad coverage for unspecified sepsis 
syndrome in the context of 
immunosuppression initiated with Tazocin 
4.5g, Gentamicin 400mg and Aciclovir 700mg 
intravenously. CT head revealed reduced grey-
white differentiation, diffuse cerebral 
swelling, bilateral temporal horn distension 
and cisternal effacement [see figure 1a] 
  
consistent with severe meningoencephalitis 
and precluding safe lumbar puncture for CSF 
study. Laboratory studies demonstrated a 
grossly elevated C reactive protein in the 
absence of a peripheral leucocytosis, typical 
of a Sepsis/Systemic Inflammatory Response 
Syndrome in the context of 
immunosuppression [see table 1]. 
Eight hours after admission her pupils became 
fixed and asymmetric. An external ventricular 
drain was placed in the right lateral ventricle 
to allow decompression of intracranial 
pressures recorded in excess of 30cmCSF. The 
CSF was clear and colourless, only 5 white 
cells, 279 red cells, protein of .33g/l and a 
raised glucose gradient of 2.8mmol/l in CSF vs. 
8.1mmol/l in serum.  
Antimicrobial therapy was switched to 
ceftriaxone 2g b.d. with aciclovir 700mg t.d.s. 
and with the suspicion of listeriosis, 
amoxicillin 2g four hourly was commenced.  
Electroencephalography demonstrated a 
globally isoelectric recording and a full 
dependence on ventilator support ensued 
with loss of self-initiated respirations. 
Repeat cranial CT imaging with angiographic 
sequences revealed severe global cerebral 
oedema with worsening cisternal effacement 
and generally poor angiographic flow and 
incipient herniation despite adequate 
positioning of the external ventricular drain 
[see figure 1b]. 
PCR on the CSF yielded a positive result for 
Listeria monocytogenes. Despite resolution of 
pyrexia and improving inflammatory indices a 
diagnosis of brain death was recorded at 60 
hours following admission. Cultures of blood 
and CSF later supported the diagnosis of 
listeriosis.  
 
 
Discussion 
Although the risk of opportunistic and atypical 
infections in the context of 
immunosuppression is familiar, the particular 
vulnerability to listeriosis in the acute phase 
following Alemutuzumab administration is not 
broadly appreciated.  
In this case as with others in the literature(10-
13), the patient did not have clear exposure to 
foodstuffs classically associated with 
heightened listeria risk.  The patient had been 
concordant with our local dietary guidelines 
(first two weeks post Alemtuzumab 
commencement) formally issued to patients 
undergoing Alemtuzumab therapy. At the 
time there was no mandatory SPC advice in 
Europe to avoid such foodstuffs (18).  This has 
since changed as of June 2016 (17). Similarly 
with the other cases the timing appears, at 
least so far, specific to the period of maximum 
suppression of lymphocyte counts following 
the anti-CD52 effect (19).  
Rau et al.(10) suggest that the listeriosis 
arising in these patients represents a 
reactivation of latent infection from possible 
reservoirs in the gallbladder or bone marrow 
tissues due to loss of the normal defence 
afforded by CD8 T cell cytotoxic effects, which 
are singularly important in host repulsion of 
listeria intracellular bacteria (10).  As such, the 
required duration of dietary abstinence 
becomes far less clear.  This may be 
particularly important in patients exposed to 
prior immunomodulatory therapies. 
The typical CSF picture associated with listeria 
is one of marked neutrophilic pleocytosis, 
elevated protein and, where sampled, raised 
lactate. This is seen in 77% of cases (20), 
however this pattern may be absent and in 
this context of immunoparesis, the isolated 
hypoglycorrachia as seen here may be the 
  
sole abnormality in addition to raised 
intracranial pressure (10).  
It is recognised that while listerial meningitis 
produces the full constellation of febrile 
illness, with meningism, neurological deficit 
and sepsis syndrome, this often develops 
subacutely, with gastroenteritis and non-
specific malaise dominating initially (10, 20). 
Timely diagnosis is further hindered by the 
prevalence, as seen in both trials and clinical 
practice, of near ubiquitous malaise, 
headache symptoms and low grade pyrexia 
with Alemtuzumab administration (2, 4, 11, 
21).    
The timing of listeriosis here in relation to 
therapy, as with the other reported cases, 
strongly suggests a causal relationship. 
However the timing and nature of prior 
disease modifying therapy is also an 
important consideration.  
The decision to escalate from dimethyl 
fumarate to Alemtuzumab was stimulated by 
further clinical relapse activity whilst on the 
former.  On the basis of published 
pharmacokinetic data for dimethyl fumarate 
(EMA Summary of Product Characteristics) a 
month-long period of washout was 
undertaken prior to Alemtuzumab initiation. 
The haematologic profile at baseline did 
demonstrate a very mild lymphopenia that 
was considered acceptable.  
The time spent off therapy was considered to 
pose significant risk of further relapses and 
the hazards of irreversible damage or limiting 
function inherent to them. The phenomenon 
of ‘rebound relapse’ after disease modifying 
therapy discontinuation, or at least return to 
baseline relapse rates is well described (22-
24). 
Other reported cases of listeriosis/listeria 
meningitis have similarly affected individuals 
completing Alemtuzumab administration after 
experiencing relapsing disease uncontrolled 
by a range of licensed therapies with varying 
modes of action (10-13).  
With the growing move toward ‘No Evidence 
of Disease Activity’ as a treatment target and 
with no currently available therapy achieving 
this in more than 50% of patients over an 
initial 2 year period even with Alemtuzumab 
(25, 26)  a growing number of patients will be 
deemed to require escalation. Despite the 
vast number of permutations of treatment 
combinations and their timings, MS physicians 
currently have comparatively little non-trial 
data on the risks thereof to guide informed 
decision making. Caution is therefore 
mandatory.   
With respect to mitigating future risks of 
listeriosis with Alemtuzumab, dietary 
guidance alone may be insufficient and CSF 
analysis on all patients with headache is 
impractical and not without its own risk. We 
therefore advocate a high index of suspicion 
and low threshold for empirical therapy in all 
those with progressive systemic symptoms or 
headache, or fever in the days and weeks 
following Alemtuzumab administration to 
avoid further mortality from listeriosis in this 
context.  
Alternatively, prophylactic cover of listeriosis 
using antibiotics such as Co-Trimoxazole, as 
used in other specialist areas using higher 
dose Alemtuzumab (27-29) could be 
considered.  Although Co-Trimoxazole in itself 
may pose adverse reactions. 
 
Conclusion 
Alemtuzumab therapy appears to confer a 
specific vulnerability to Listeria 
monocytogenes infection. This led to mortality 
from a very rapidly progressive 
meningoencephalitis following otherwise 
  
routine administration in a typical case of 
multiple sclerosis. Preceding disease 
modifying therapy may modify risk in a 
currently unquantified manner and high 
vigilance for this complication is needed. The 
speed of onset in this case should raise 
awareness of the need to see such patients 
without delay to minimise risk.  
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